Colin Galbraith
Tracked across 2 events · 26 articles · First seen Aug 03, 2026 · Last active Aug 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Colin Galbraith, AstraZeneca's executive vice president for oncology R&D, commented on the trial discontinuation, expressing disappointment and commitment to learning from the trial.
Aug 17, 2026 · 20 articles
Regulatory
Impact: Colin Galbraith, chairman of United Kingdom — NatureScot, thanked officials for handling the licence application professionally.
Aug 03, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Colin Galbraith live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard